CEL-SCI (AMEX:CVM) traded at a new 52-week low today of $0.26. This new low was reached on below average trading volume as 259,000 shares traded hands, while the average 30-day volume is approximately 1.2 million shares.

Over the past year, CEL-SCIhas traded in a range of $0.26 to $0.65 and are now at $0.26. Over the past week, the 200-day moving average (MA) has gone down 1.3% while the 50-day MA has declined 0.7%.

Potential upside of 197.5% exists for CEL-SCI, based on a current level of $0.26 and analysts' average consensus price target of $0.78. The stock should find initial resistance at its 50-day moving average (MA) of $0.28 and further resistance at its 200-day MA of $0.34.

CEL-SCI Corporation researches and develops certain drugs and vaccines. The Company's Multikine is being tested to determine if it is effective in improving the immune response of cancer patients. CEL-SCI is also developing other products. The Company is currently targeting diseases such as AIDS, herpes simplex, malaria, tuberculosis, prostate cancer, and breast cancer.

SmarTrend recommended that its subscribers protect gains by selling shares of CEL-SCI on May 21st, 2012 by issuing a Downtrend alert when the shares were trading at $0.40. Since that call, shares of CEL-SCI have fallen 34.2%. We are now looking for when a new Uptrend will commence and will alert SmarTrend subscribers in real time.